{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:14:34Z","timestamp":1783379674461,"version":"3.54.6"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015631","name":"Merck Canada Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021981","name":"Hoffmann-La Roche Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013739","name":"Pfizer Canada ULC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023368","name":"Eisai Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb Canada Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.urolonc.2026.05.016","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:20:01Z","timestamp":1781000401000},"page":"138-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of partial nephrectomy to radical nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian Multi-Institutional Collaborative"],"prefix":"10.1016","volume":"44","author":[{"given":"Rahul K.","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2782-0648","authenticated-orcid":false,"given":"Raees","family":"Cassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeeta","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles P","family":"Mannas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tanguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke T.","family":"Lavall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmir G","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo A.","family":"Rendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal","family":"Bhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Lattouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly-Khan A","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney H.","family":"Breau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.05.016_bib0001","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/JU.0000000000001911","article-title":"Renal mass and localized Renal cancer: evaluation, management, and follow-up: AUA guideline: part I","volume":"206","author":"Campbell","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0002","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1464-410X.2006.06060.x","article-title":"Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4\u20137 cm","volume":"97","author":"Dash","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0003","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1464-410X.2011.10597.x","article-title":"Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach","volume":"109","author":"Badalato","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0004","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.urology.2008.08.492","article-title":"Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics","volume":"73","author":"Jeldres","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0005","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.eururo.2006.11.013","article-title":"A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma","volume":"51","author":"Van Poppel","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0006","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/lap.2016.0668","article-title":"Retroperitoneal laparoscopic partial nephrectomy for tumors larger than 7\u2009cm in renal cell carcinoma: initial experience of single-institution","volume":"27","author":"Song","year":"2017","journal-title":"J Laparoendosc Adv Surg Tech A"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184431","article-title":"On-clamp vs. Off-clamp robot-assisted partial nephrectomy for cT2 renal tumors: retrospective propensity-score-matched multicenter outcome analysis","volume":"14","author":"Brassetti","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0008","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.eururo.2016.08.060","article-title":"Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies","volume":"71","author":"Mir","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0009","article-title":"Partial nephrectomy versus radical nephrectomy for clinical T2 or higher stage renal tumors: a systematic review and meta-analysis","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0010","doi-asserted-by":"crossref","DOI":"10.5489\/cuaj.6716","article-title":"Determining generalizability of the Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population: generalizability of CKCis to the entire Canadian RCC population","volume":"14","author":"Tajzler","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5489\/cuaj.5462","article-title":"Canadian Urological Association guideline for follow-up of patients after treatment of non-metastatic renal cell carcinoma","volume":"12","author":"Kassouf","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0012","series-title":"RStudio: integrated development for r","year":"2022"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0013","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1464-410X.2007.07225.x","article-title":"Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma","volume":"100","author":"Margulis","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0014","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.juro.2009.11.037","article-title":"Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy","volume":"183","author":"Breau","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0015","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1089\/end.2017.0190","article-title":"Matched comparison between partial nephrectomy and radical nephrectomy for T2 N0 M0 tumors, a study based on the National Cancer Database","volume":"31","author":"Shum","year":"2017","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0016","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/MOU.0000000000001286","article-title":"Salvage treatment of local recurrence following radical and partial nephrectomy","volume":"35","author":"Perri","year":"2025","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0017","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bju.12580","article-title":"Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score","volume":"114","author":"Kopp","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0018","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00345-019-02994-2","article-title":"Robotic partial nephrectomy for clinical T2a renal mass is associated with improved trifecta outcome compared to open partial nephrectomy: a single surgeon comparative analysis","volume":"38","author":"Ghali","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0019","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bju.15064","article-title":"Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group","volume":"126","author":"Bradshaw","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0020","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0021","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2014.09.027","article-title":"Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a\u2013T1b renal mass and normal preoperative renal function","volume":"67","author":"Capitanio","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0022","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.juro.2008.09.017","article-title":"Partial nephrectomy versus radical nephrectomy in patients with small renal tumors\u2014Is there a difference in mortality and cardiovascular outcomes?","volume":"181","author":"Huang","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0023","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.urology.2011.10.073","article-title":"Functional analysis of elective nephron-sparing surgery vs radical nephrectomy for renal tumors larger than 4 cm","volume":"79","author":"Roos","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0024","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.purol.2018.03.009","article-title":"Nephron sparing surgery in tumours greater than 7 cm","volume":"28","author":"De Saint Aubert","year":"2018","journal-title":"Progr\u00e8s En Urologie"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196427","article-title":"Survival outcomes in patients with large (\u22657cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: results of a multicenter cohort with long-term follow-up","volume":"13","author":"Janssen","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0026","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.purol.2017.12.004","article-title":"Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: a collaborative international study from the French kidney cancer research network UroCCR","volume":"28","author":"Reix","year":"2018","journal-title":"Progr\u00e8s En Urologie"},{"key":"10.1016\/j.urolonc.2026.05.016_bib0027","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/iju.14664","article-title":"Partial versus radical nephrectomy in clinical T2 renal masses","volume":"28","author":"Klett","year":"2021","journal-title":"Int J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:29:17Z","timestamp":1783376957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1078143926005375"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of partial nephrectomy to radical nephrectomy for non-metastatic cT2 renal tumors: Results from a Canadian Multi-Institutional Collaborative","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}